BBIO
What one share of BridgeBio Pharma holds
Pharmaceutical Preparations
BridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases. We seek to translate advances in genetic science into therapies for patient populations with significant unmet medical needs.
BridgeBio Pharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.68 |
|---|---|
| Profit | −$3.57 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$2.24 |
| Cash and investments | $3.47 |
| Debt | $13.58 |
| Book value | −$12.88 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$1.00 | $0.02 | −$1.34 | — | $2.81 |
| 2018 | — | −$2.12 | $0.04 | −$2.25 | — | $3.42 |
| 2019 | $0.39 | −$2.48 | $0.03 | −$2.44 | — | $3.30 |
| 2020 | $0.07 | −$3.80 | $0.06 | −$3.45 | — | $0.47 |
| 2021 | $0.48 | −$3.90 | $0.09 | −$3.54 | — | −$5.91 |
| 2022 | $0.53 | −$3.26 | $0.03 | −$2.88 | — | −$8.33 |
| 2023 | $0.06 | −$3.95 | $0.01 | −$3.25 | — | −$7.73 |
| 2024 | $1.19 | −$2.88 | $0.01 | −$2.80 | — | −$7.72 |
| 2025 | $2.62 | −$3.79 | $0.01 | −$2.33 | — | −$10.71 |